Products

Health is our passion and priority

Health is our passion and priority

Please see below a list of Astellas’ medicines with links to the Summary of Product Characteristics and Patient Leaflets for each provided:

Patients should always consult with their healthcare professional for any further information about their specific treatment.

 

Haematology

XospataTM(gilteritinib fumarate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

Oncology

PadcevTM(enfortubmab vedotin) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

XtandiTM (enzalutamide) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

VyloyTM (zolbetuximab) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

Renal

EvrenzoTM(roxadustat) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

Transplantation

Advagraf TM(tacrolimus monohydrate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

ModigrafTM (tacrolimus monohydrate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

PrografTM (tacrolimus monohydrate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

Urology

Flowmaxtra XLTM (tamsulosin hydrochloride) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

Mirabegron-Astellas (mirabegron) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

VesomniTM (tamsulosin hydrochloride, solifenacin succinate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

VesicareTM (solifenacin succinate) | Summary of Product Characteristics (SmPC) | Patient Leaflet (PIL)

Women’s Health

VeozaTM(fezolinetant) | Summary of Product Characteristics▼ (SmPC) | Patient Leaflet (PIL)

MAT-GB-NON-2024-00706 / November 2024